ZyVersa Therapeutics Bolsa (NASDAQ: ZVSA)

Últimas noticias sobre ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

JP Morgan analyst Rodolfo Angele upgrades Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) from Underweight to Neutral and raises the price target from $7.5 to $9.5.

News

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Ecopetrol to Neutral, Raises Price Target to $9.5

U.S. stock futures were mixed on Thursday after a hotter-than-expected January inflation print, which was released on Wednesday.
The S&amp;P 500 and Dow Jones declined in premarket, whereas Nasdaq 100 and Russell 2000 were up.
Traders await the headline and core producer price index data for January which will be released before the market opens.
The 10-year Treasury yield stood at 4.61%, while the two-year yield was at 4.34%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool,</a> there is a 97.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.11%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.03%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.01%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.30%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were mixed in premarket trading on Thursday. SPY fell 0.013% to $603.28, and QQQ was up 0.15% to $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stocks mostly declined on Wednesday after January&#8217;s CPI exceeded expectations at 3% year-over-year and 0.5% monthly, which was the fastest pace of growth since August.
Materials, energy, and real estate sectors led losses, while consumer staples and communication services advanced.
Megacap tech like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) fell, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rebounded over 2% after a five-day losing streak. CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) surged 15% on strong earnings.
The Dow fell 225 points or 0.50% to 44,368.56, the S&amp;P 500 was down 0.27% and closed at 6,051.97, and the Nasdaq Composite was above the flatline by 0.031% at 19,649.95. Russell 2000 Index fell 0.87% to 2,255.89.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.031%</td>
<td>19,649.95</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.27%</td>
<td>6,051.97</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.50%</td>
<td>44,368.56</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.87%</td>
<td>2,255.89</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
As President Donald Trump&#8216;s policies begin to take shape, Louis Navellier of Navellier &amp; Associates said that investors should not expect immediate action from the Federal Reserve, as the central bank is likely to remain on the sidelines until there is more clarity on which proposals will be enacted.
However, he said that despite the uncertainty surrounding Trump's new agenda, earnings remain strong, and consumer spending continues, suggesting positive momentum, though tempered with caution. As the details of the administration&#8217;s plans unfold, both the market and the Fed are likely to remain in a wait-and-see mode.
Ed Yardeni and Eric Wallerstein from Yardeni Research highlighted that the policy side effects of Trump 2.0 go beyond just Fed-related economic data, such as inflation and labor market reports. They pointed out that President Trump's announcement that Russia had agreed to start negotiations &#8220;immediately&#8221; to end the war in Ukraine provided a boost to stocks.
Talking about Wednesday&#8217;s CPI print, Subho Moulik, Founder &amp; CEO, Appreciate said that higher inflation could prompt policymakers in Washington to maintain a higher-for-longer stance—as seen in December 2024 when a marginal CPI beat reinforced the Fed's cautious approach.
&#8220;This hawkish tilt could push U.S. bond yields higher, strengthen the dollar, and trigger further capital outflows from emerging markets,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul>
<li>Initial jobless claims till Feb. 8 will be out at 8:30 a.m., ET.</li>
<li>The headline and core producer price index data for January will be released at 8:30 a.m., ET as well.</li>
</ul>
Stocks In Focus:
<ul>
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) was down 0.32% in premarket on Thursday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $3.11 per share on revenue of $7.70 billion.</li>
<li>GE Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) rose 0.13% as Wall Street expects it to report quarterly earnings of $1.26 per share on revenue of $5.33 billion before the opening bell.</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) declined 0.26% ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of $3.94 per share on revenue of $1.32 billion.</li>
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) advanced 3.31% ahead of its earnings, which will be released after the closing bell. Analysts expect it to report quarterly earnings of $1.81 per share on revenue of $1.83 billion.</li>
<li>Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) was down 0.1% as Wall Street expects it to report quarterly earnings of $2.29 per share on revenue of $7.14 billion after the closing bell.</li>
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) was up 5.97% after it reported better-than-expected second-quarter earnings and revealed an AI order pipeline of $700 million for the six months ended Jan. 25.</li>
<li>Fastly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) dropped 20.26% after it reported a fourth-quarter loss of 3 cents per share. Whereas, the quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate.</li>
<li>HubSpot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) was higher by 5.74% after it reported stronger-than-expected results for its fourth quarter.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.42% to hover around $70.36 per barrel.
The gold spot index was up by 0.43% to $2,916.84 per ounce. The Dollar Index was down 0.3% at 107.615 level.
Asian markets were mixed on Thursday as India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, and China's CSI 300 index declined. Australia's ASX 200, South Korea's Kospi, and Japan's Nikkei 225 index advanced. European markets were mostly higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43684201/cvs-health-forecasts-10-earnings-growth-for-2025-citing-aetnas-meaningful-recovery">CVS Health Forecasts 10% Earnings Growth For 2025, Citing Aetna&#8217;s &#8216;Meaningful Recovery&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Macro Notification

Market Summary

Futures

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

AMAT

AMZN

COIN

CSCO

FSLY

GEHC

GOOG

GOOGL

HUBS

TSLA

ZBRA

US Stocks Set For A Mixed Start Following Higher Inflation Print: Expert Says Earnings Remain Strong Despite Uncertainty

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is trading 2.2% higher in pre-market on Thursday following upbeat analyst calls on the stock as well as news over new EV taxes to finance road repairs which could impact its rivals.
What Happened: Today, Wedbush Securities analyst Dan Ives <a href="https://www.benzinga.com/25/02/43682491/elon-musks-doge-dedication-sparks-tesla-brand-deterioration-as-ev-maker-drops-20-after-trump-inauguration-dan-ives-says-bark-way-worse-than-the-bite">maintained his bullish stance</a> on Tesla and his $550 price target on the stock, despite concerns over Musk&#8217;s dedication to DOGE, causing potential brand deterioration.
Similarly, on Wednesday, Analyst Mickey Legg from Benchmark Equity placed a &#8216;Buy&#8217; rating and a $475 price target on the stock. He identified major growth drivers for Tesla in the fields of <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43675344/tesla-jumps-as-analyst-highlights-growth-in-evs-ai-robotics">autonomous vehicles, robotics, and energy generation </a>and storage. 
In another development, the U.S. Senate Republicans, on Wednesday, proposed two bills to remove the country&#8217;s $7,500 electric vehicle tax credit and introduce a new $1,000 tax on EVs to support road maintenance. This is likely to come as a blow to Tesla rivals like General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) who have been <a href="https://www.benzinga.com/markets/25/02/43648415/tesla-rivals-call-for-gradual-elimination-of-ev-tax-credits-many-of-those-jobs-will-be-at-risk">pushing for a gradual phase out </a>of the EV tax credits. Tesla has always maintained its stance on the elimination of EV subsidies.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43681521/cathie-wood-dumps-more-palantir-amid-stocks-red-hot-rally-robinhood-also-gets-the-chop-ark-adds-amd-and-tsmc-stock">Cathie Wood Dumps More Palantir Amid Stock&#8217;s Red-Hot Rally, Robinhood Also Gets The Chop — Ark Adds AMD And TSMC Stock</a>
Why It Matters: Tesla&#8217;s growth prospects have been a topic of discussion, especially with CEO Elon Musk&#8217;s involvement in various ventures. 
Despite regulatory uncertainty and increasing EV competition putting downward pressure on vehicle pricing, analyst Mickey Legg is confident that Tesla&#8217;s product range will help mitigate these challenges. With $36.5 billion in cash and investments, the Elon Musk-led company is well-placed to pursue significant expansion possibilities, as per Legg. 
These events highlight the dynamic nature of Tesla&#8217;s operations and the potential impact of external factors on its growth trajectory.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/02/43686104/mitch-mcconnell-criticizes-trumps-tariff-plans-warns-of-potential-price-hike-big-lingering-concerns-for-american-industry-and-workers">Mitch McConnell Criticizes Trump&#8217;s Tariff Plans, Warns Of Potential Price Hike: &#8216;Big, Lingering Concerns For American Industry And Workers&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

Tesla Stock Climbs Over 2% In Thursday Pre-Market: What's Going On?

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and lowers the price target from $94 to $84.

CRSP

Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84

Jefferies analyst Omar Nokta maintains Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) with a Buy and maintains $75 price target.

STNG

Jefferies Maintains Buy on Scorpio Tankers, Maintains $75 Price Target

Piper Sandler analyst Joseph Catanzaro initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight rating and announces Price Target of $84.

Initiation

MRUS

Piper Sandler Initiates Coverage On Merus with Overweight Rating, Announces Price Target of $84

President Donald Trump has nominated Jonathan Morrison to be administrator of the U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) responsible for overseeing safety probes into multiple automakers including Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
What Happened: The nomination was referred to Committee on Commerce, Science, and Transportation, the record show, following which it would be sent for a full Senate vote. 
According to Morrison&#8217;s LinkedIn profile, he is currently an Apple employee who previously served as chief counsel of NHTSA during Trump&#8217;s previous term. He was also formerly the Director of Legal &amp; Regulatory Affairs of the California New Car Dealers Association.
If sworn in, Morrison will oversee the agency that probes automakers, including Elon Musk&#8217;s Tesla, over safety concerns. 
Last month the Department of Transportation Secretary Sean Duffy <a href="https://www.benzinga.com/markets/equities/25/01/43020202/trumps-dot-pick-assures-ongoing-tesla-fsd-investigation-and-rigorous-oversight-of-boeing">committed to allowing the NHTSA to proceed </a>with its investigation into Tesla's Full Self-Driving (FSD) software. 
"I commit to this committee and to you that I will let NHTSA do their investigation," Duffy said when asked if Musk&#8217;s proximity to President Trump will impact ongoing investigations. Musk is leading the department of government efficiency under the Trump administration. 
Why It Matters: In January, NHTSA opened a probe&nbsp;<a href="https://www.benzinga.com/25/01/42840097/nhtsa-opens-probe-into-26-million-tesla-vehicles-after-complaint-of-crash-involving-actually-smart-summon-feature" target="_blank" rel="noreferrer noopener">into about 2.6 million Tesla vehicles</a>&nbsp;equipped with the company's full self-driving driver assistance technology following a complaint alleging that the use of its "Actually Smart Summon" feature led to a crash.
Actually Smart Summon refers to a feature that allows a user to remotely move the vehicle towards themselves or to another nearby location such as a parking lot through the company's phone app.
In October, NHTSA opened an investigation into<a href="https://www.benzinga.com/news/24/10/41398764/nhtsa-opens-probe-into-2-4m-tesla-vehicles-after-reports-of-4-crashes-with-fsd-involved" target="_blank" rel="noreferrer noopener">&nbsp;2.4 million Tesla vehicles</a>&nbsp;following reports of four crashes where FSD was engaged. 
The regulator then said that it had identified four crash reports in which a Tesla experienced a crash after entering an area of &#8220;reduced roadway visibility&#8221; with FSD engaged.&nbsp;The reduced visibility, the regulator said, was caused by sun glare, fog, or airborne dust.
In one of the crashes, the vehicle struck and killed a pedestrian, the regulator added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43684382/tesla-offers-discounts-up-to-6000-on-model-year-2024-cybertrucks-in-inventory" target="_blank" rel="noreferrer noopener">Tesla Hikes Discounts On Cybertrucks By 3X To $6000 As It Looks To Clear 2024 Inventory</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Trump Nominates Apple Employee To Oversee Safety Probes Multiple Automakers, Including Elon Musk's Tesla

Canaccord Genuity analyst Joseph Vafi maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and raises the price target from $17 to $23.

IREN

Canaccord Genuity Maintains Buy on IREN, Raises Price Target to $23

The solution harmonizes data from organizations' most mission-critical applications with data engineering and business analytics capabilities, paving the way for next-level innovation and insights.
SAP today also announced a powerful new agent builder capability, so customers can build and deploy their own AI agents alongside SAP's library of ready-to-deploy Joule agents.

SAP Unveils Business Data Cloud With Databricks; Also Announces New Agent Builder Capability

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and raises the price target from $70 to $73.

Telsey Advisory Group Maintains Outperform on Kroger, Raises Price Target to $73

Piper Sandler analyst Alexander Goldfarb downgrades Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) from Overweight to Neutral and lowers the price target from $33 to $25.

Downgrades

Piper Sandler Downgrades Kite Realty Gr Trust to Neutral, Lowers Price Target to $25

The partnership will enable Ooredoo to expand its MENA footprint of hyperscale and AI data centre infrastructure, combining the strength of the company's local development and operational track record with Iron Mountain's global operating expertise.
 &nbsp;

Iron Mountain To Take Minority Equity Stake In Ooredoo's Data Centre Company MENA Digital Hub, No Terms Disclosed

Telsey Advisory Group analyst Dana Telsey maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and maintains $70 price target.

BIRK

Telsey Advisory Group Maintains Outperform on Birkenstock Holding, Maintains $70 Price Target

Supported by today's announcement that Forschungszentrum Jülich (FZJ) is the first high-performance computing (HPC) center in the world to purchase a D-Wave Advantage quantum system, D-Wave expects the new systems offering to drive advanced research and new discoveries in areas such as artificial intelligence (AI) and quantum simulation.
The Company also announced the new "Quantum Uplift" program to address the growing number of customers expressing disappointment with competitor quantum systems that are incapable of solving problems of practical value and lack reliable uptime and availability.&nbsp;

QBTS

D-Wave Quantum Reveals On-Premises Systems Offering; Also Unveils Quantum Uplift Program

Non-Executive Board Chair Nancy E. Cooper will remain on the Brunswick Board and current Board member David E. Everitt will assume the role of Lead Independent Director.
Foulkes was appointed Chief Executive Officer and a member of the Board of Brunswick Corporation in January 2019.

Management

Brunswick Board Elects CEO David M. Foulkes As Chairman Of Board, Effective March 1

Seaport Global analyst Tom Curran downgrades Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral.

ASPN

Seaport Global Downgrades Aspen Aerogels to Neutral

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance <a href="https://www.benzinga.com/news/earnings/25/02/43676556/applovin-stock-soars-on-q4-earnings-revenue-beat-eps-beat-strong-guidance-and-more">above estimates</a>.
Applovin reported fourth-quarter revenue of $1.37 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported fourth-quarter earnings of $1.73 per share, beating analyst estimates of $1.25 per share.
AppLovin shares jumped 28.9% to $490.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) gained 81.2% to $0.4570 in pre-market trading after the company said third-quarter revenue jumped 1,557% year-over-year to $4.77 million.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 42% to $0.9937 in pre-market trading. Tivic Health Systems shares jumped 198% on Wednesday after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares jumped 45.6% to $0.6701 in pre-market trading.</li>
<li>MGO Global, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 38.5% to $0.6326 in pre-market trading after dipping 24% on Wednesday.</li>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) gained 26% to $0.3535 in pre-market following a 7% gain in the previous session.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares climbed 24.6% to $80.72 in pre-market trading following better-than-expected fourth-quarter financial results.</li>
<li>Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) gained 19.4% to $11.99 in pre-market trading after dipping 10% on Wednesday.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 15.6% to $64.72 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>CEVA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) gained 8.5% to $34.41 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares fell 30.6% to $8.15 in pre-market trading after the company issued first-quarter guidance below estimates.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) dipped 27% to $89.34 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Omega Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) fell 24.6% to $0.1960 in today's pre-market trading after surging 35% on Wednesday. Omega Therapeutics' restructuring committee recently approved a workforce reduction of up to 17 employees for cost-reduction amid a Chapter 11 case and potential asset sale.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 24.4% to $0.6363 in pre-market trading. NKGen Biotech shares jumped 122% on Wednesday after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer&#8217;s disease.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) fell 23.7% to $0.4730 in pre-market trading after jumping 134% on Wednesday.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares tumbled 20.6% to $8.00 in pre-market trading. Fastly reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 18.1% to $3.30 in pre-market trading.</li>
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 14.5% to $2.1800 in pre-market trading after the company announced the pricing of public offering of common shares.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 14.1% to $185.94 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Open Lending Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) shares dipped 13% to $5.02 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

ATAI

AVGR

BROS

CEVA

HOOD

LPRO

MGOL

MYNA

NKGN

OMGA

PRPH

RDDT

SLSR

TIVC

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">First Quarter 2025 Guidance &nbsp;</td>
</tr>
<tr>
<td>Net Revenue:</td>
<td>Decrease 8.5% to 12.5% QoQ, Flat to Up 4.6% YoY</td>
</tr>
<tr>
<td>Gross Margin:</td>
<td>Around 30.5%, depending on final product mix</td>
</tr>
<tr>
<td>Profit:</td>
<td>9.0 cents to 11.0 cents per diluted ADS, Up 26% to 54% YoY&nbsp;&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Guidance

HIMX

Himax Technologies Expects Q1 Revenue Growth Of Flat To 4.6% YoY Vs $200.7M Est, EPADS Of $0.09-$0.11 Vs $0.08 Est

TD Securities analyst Andrew Charles maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Buy and raises the price target from $65 to $89.

TD Securities Maintains Buy on Dutch Bros, Raises Price Target to $89

<h2>Nissan Motor Co., Ltd. ("Nissan") and Honda Motor Co., Ltd. ("Honda") , today agreed to terminate the MOU signed on December 23 last year for consideration of a business integration between the two companies.</h2>
https://global.honda/en/newsroom/news/2025/c250213aeng.html

NSANY

Earlier Nissan, Honda Announced Termination Of MOU For Consideration Of Business Integration

Warning: ZVSA is at high risk of performing badly

ZyVersa Therapeutics (ZVSA) highlights data from a review article published in the peer-reviewed journal, Life. The article summarizes data from 34...

ZyVersa highlights review article on inflammasome-induced inflammation

An announcement from ZyVersa Therapeutics ( ($ZVSA) ) is now available. ZyVersa Therapeutics' recent annual meeting saw key shareholder approvals, ...

ZyVersa Therapeutics' Shareholder Approvals and Director Elections

Bionomics, Simpple Ltd., and ZyVersa Therapeutics are the 3 Penny Stocks to watch on November 7, 2024, based on&nbsp;TipRanks' Penny Stock Screener...

3 Penny Stocks to Watch Now, 11/7/24

ZyVersa Therapeutics GAAP EPS of -$2.43 misses by $0.83

Zyversa Therapeutics, Inc. ( ($ZVSA) ) has released its Q3 earnings. Here is a breakdown of the information Zyversa Therapeutics, Inc. presented to...

ZyVersa Therapeutics Reports Q3 Progress and Outlook

ZyVersa Therapeutics (ZVSA) announces newly published data demonstrating that stroke-related cardiovascular injury and dysfunction is induced by AI...

ZyVersa Therapeutics announces publication on ASC Inhibitor IC 100

17:08 EST ZyVersa Therapeutics (ZVSA) files to sell 1.64M shares of common stock for holders Published first on TheFly – the ultimate source for re...

ZyVersa Therapeutics files to sell 1.64M shares of common stock for holders

BNOX

SPPL

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

Biotech

General

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Health Care

Press Releases

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge"

Earnings

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Comments

ZyVersa Therapeutics

Noticias

Últimas noticias sobre ZyVersa Therapeutics (NASDAQ:ZVSA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL